…
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CellaVision AB makes digital cell-imaging systems and software that automate microscopic analysis of blood and body-fluid samples for clinical hematology labs. Long-term growth may be supported by rising demand for laboratory automation, aging populations increasing diagnostic volumes, and broader adoption of digital workflows with recurring software and service revenue. The company appears positioned to benefit from a focused niche and expanding installed base.
Principal risks include competition from large diagnostics firms and new AI entrants, regulatory and reimbursement uncertainty, reliance on hospital purchasing cycles, and execution risk in international expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 194.26M | 176.86M | 164.22M | 148.43M | 158.30M |
| Net income | 153.08M | 140.72M | 130.31M | 118.33M | 125.34M |
| Selling general administrative | 90.34M | 85.36M | 76.03M | 191.50M | 165.32M |
| Selling and marketing expenses | 129.88M | 136.59M | 136.62M | - | - |
| Gross profit | 519.88M | 487.07M | 463.04M | 438.32M | 392.30M |
| Reconciled depreciation | 40.05M | 41.01M | 39.76M | 40.10M | 33.44M |
| Ebit | 204.46M | 178.75M | 167.48M | 158.27M | 162.73M |
| Ebitda | 236.69M | 219.75M | 207.25M | 190.87M | 193.60M |
| Depreciation and amortization | 32.23M | 41.01M | 39.76M | - | - |
| Operating income | 202.07M | 177.68M | 167.05M | 158.27M | 162.73M |
| Other operating expenses | 556.89M | 545.54M | 510.24M | - | - |
| Interest expense | 10.71M | 1.89M | 3.26M | 2.34M | 1.87M |
| Tax provision | 41.19M | 36.14M | 28.77M | 30.09M | 32.96M |
| Interest income | 2.90M | 7.34M | 0.78M | 0.20M | 0.06M |
| Net interest income | -7.81M | -0.82M | 5.08M | -2.14M | -1.81M |
| Income tax expense | 41.19M | 36.14M | 33.91M | 30.09M | 32.96M |
| Total revenue | 758.97M | 723.22M | 677.29M | 639.34M | 565.55M |
| Total operating expenses | 317.80M | 309.39M | 295.99M | 481.07M | 402.82M |
| Cost of revenue | 239.09M | 236.14M | 214.25M | 201.02M | 173.25M |
| Total other income expense net | -7.81M | -0.82M | -2.83M | - | - |
| Net income from continuing ops | 153.08M | 140.72M | 112.17M | 118.33M | 125.34M |
| Net income applicable to common shares | - | - | - | 118.33M | 125.34M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1094.89M | 1013.05M | 928.71M | 891.75M | 825.21M |
| Intangible assets | 408.20M | 359.51M | 99.58M | 275.09M | 244.07M |
| Other current assets | - | 2.12M | 20.11M | 0.87M | 0.90M |
| Total liab | 207.31M | 196.16M | 212.32M | 250.12M | 281.93M |
| Total stockholder equity | 887.58M | 815.73M | 716.39M | 641.63M | 543.28M |
| Deferred long term liab | - | - | - | 162.71M | 126.28M |
| Other current liab | 61.52M | 61.55M | 49.93M | 7.64M | 14.14M |
| Common stock | - | 3.58M | 3.58M | 3.58M | 3.58M |
| Capital stock | 3.58M | 3.58M | 3.58M | 3.58M | 3.58M |
| Retained earnings | 865.07M | 771.62M | 684.56M | 607.92M | 537.28M |
| Other liab | - | - | - | 56.66M | 51.59M |
| Good will | 120.68M | 128.14M | 123.78M | 124.14M | 114.08M |
| Other assets | - | -0.00M | 0.00M | 168.05M | 148.28M |
| Cash | 188.22M | 149.43M | 121.64M | 108.05M | 130.29M |
| Total current liabilities | 110.93M | 107.95M | 119.15M | 133.09M | 134.50M |
| Current deferred revenue | - | - | 0.00M | - | - |
| Net debt | -162.56M | -122.58M | -56.94M | - | - |
| Short term debt | 13.68M | 14.17M | 36.04M | - | - |
| Short long term debt | 13.68M | 14.17M | 36.04M | 42.13M | - |
| Short long term debt total | 25.65M | 26.85M | 64.70M | - | - |
| Other stockholder equity | 887.58M | 10.80M | 28.25M | 19.33M | -8.38M |
| Property plant equipment | - | - | - | 110.03M | 80.33M |
| Total current assets | 441.09M | 401.65M | 365.59M | 377.14M | 364.72M |
| Net tangible assets | - | - | - | 405.11M | 311.39M |
| Net receivables | 141.07M | 125.28M | 97.80M | 121.89M | 115.50M |
| Long term debt | 11.97M | 12.68M | 28.66M | 60.36M | - |
| Inventory | 111.81M | 124.82M | 126.04M | 142.57M | 115.09M |
| Accounts payable | 35.73M | 32.22M | 32.53M | 47.86M | 44.86M |
| Accumulated other comprehensive income | - | 29.73M | 17.45M | - | - |
| Non currrent assets other | 0.01M | 2.65M | 214.26M | -0.00M | - |
| Non current assets total | 653.79M | 610.24M | 563.12M | 514.60M | 460.49M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.11M | -76.01M | -87.69M | -0.58M | -0.03M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -86.16M | -76.01M | -85.53M | -70.01M | -84.34M |
| Net borrowings | -1.60M | -28.96M | -31.42M | -42.71M | -30.59M |
| Total cash from financing activities | -74.59M | -95.09M | -97.04M | -90.41M | -48.48M |
| Change to operating activities | - | - | - | 0.85M | 29.03M |
| Net income | 194.26M | 176.86M | 130.31M | 118.33M | 125.34M |
| Change in cash | 38.79M | 27.79M | 13.59M | -22.23M | 28.02M |
| Begin period cash flow | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M |
| End period cash flow | 188.22M | 149.43M | 121.64M | 108.05M | 130.29M |
| Total cash from operating activities | 200.53M | 198.44M | 196.44M | 137.28M | 159.72M |
| Depreciation | 40.05M | 41.01M | 39.76M | 33.39M | 26.69M |
| Other cashflows from investing activities | 0.00M | 1.74M | -54.71M | 0.00M | 0.00M |
| Dividends paid | 59.63M | 53.67M | 53.67M | -47.70M | -17.89M |
| Change to inventory | 4.62M | -1.71M | 12.62M | -26.32M | -31.06M |
| Change to account receivables | - | -15.80M | 7.25M | -3.33M | -9.84M |
| Other cashflows from financing activities | -13.37M | -12.46M | -11.95M | - | 0.00M |
| Change to netincome | - | - | - | 7.66M | 12.81M |
| Capital expenditures | 86.27M | 77.75M | 86.48M | 23.48M | 13.72M |
| Change in working capital | -3.19M | -15.41M | 10.39M | -28.80M | -11.87M |
| Other non cash items | 9.45M | -4.01M | 15.97M | -3.14M | 6.45M |
| Free cash flow | 114.26M | 120.69M | 109.96M | 67.85M | 75.41M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D. | Founder & Director | 1965 |
| Mr. Simon Ostergaard | CEO & Pres | 1971 |
| Mr. Peter Wilson | VP of Global Marketing | 1967 |
| Mr. Yve van Thorenburg | Acting VP of Global Sales & Director of APAC of Global Sales | 1958 |
| Mr. Urban Strindlov | VP of Global Sales | 1964 |
| Nina Wallander | VP of HR | 1974 |
| Mr. Magnus Blixt | Exec. Officer | 1966 |
| Mr. Julien Veyssy | Managing Director of RAL Diagnostics | 1983 |
| Mr. Simon Ostergaard Ph.D. | CEO & President | 1971 |
| Mr. Magnus Blixt | Chief Financial Officer | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.